Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor The Prostate Cancer Precision Medicine Multi ...
The Medicare coverage memo for next-generation DNA sequencing (NGS) was reopened to allow for NGS testing for other than late-stage cancers, but stakeholders are urging the U.S. Centers for Medicare ...
Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.
To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...
From Days to Hours: MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader in molecular diagnostics, announces the integration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results